U.S. Markets closed

Neuronal Acetylcholine Receptor Subunit Beta 2, Pipeline Review, H2 2019: Assuage Pharmaceuticals Inc & Kyung Dong Co. Ltd - ResearchAndMarkets.com

The "Neuronal Acetylcholine Receptor Subunit Beta 2 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Summary

According to the recently published report 'Neuronal Acetylcholine Receptor Subunit Beta 2 - Pipeline Review, H2 2019'; Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Neuronal acetylcholine receptor subunit beta-2 is a protein encoded by the CHRNB2 gene. Acetylcholine binds to this receptor. This results in extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions.

The report 'Neuronal Acetylcholine Receptor Subunit Beta 2 - Pipeline Review, H2 2019' outlays comprehensive information on the Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 2 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System which include indications Smoking Cessation, Psychiatric Disorders, Alcohol Addiction, Major Depressive Disorder, Neurology and Nicotine Addiction.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2)
  • The report reviews Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Key Topics Covered:

  • Introduction
  • Report Coverage
  • Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Overview
  • Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Companies Involved in Therapeutics Development
  • Assuage Pharmaceuticals Inc
  • H. Lundbeck AS
  • Jeil Pharmaceutical Co Ltd
  • Kyung Dong Co Ltd
  • Sopharma AD
  • Suven Life Sciences Ltd
  • Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Drug Profiles
  • AP-202 - Drug Profile
  • cytisinicline - Drug Profile
  • JLP-1603 - Drug Profile
  • KD-8001 - Drug Profile
  • Small Molecule to Antagonize CHRNB2 and CHRNA4 for Psychiatric Disorders - Drug Profile
  • Small Molecules to Antagonize CHRNA4 and CHRNB2 for Neurological and Psychiatric disorders - Drug Profile
  • Small Molecules to Antagonize CHRNB2 and CHRNA4 for Smoking Cessation - Drug Profile
  • SUVN-911 - Drug Profile
  • varenicline tartrate - Drug Profile
  • varenicline tartrate - Drug Profile
  • Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Dormant Products
  • Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Discontinued Products
  • Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Product Development Milestones
  • Featured News & Press Releases

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/646s23

View source version on businesswire.com: https://www.businesswire.com/news/home/20200116005443/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900